The NSF-supported Biofoundry aims to develop new research, technologies, and instructional experiences in the areas of glycoenzymes and glycoproteins across the tree of life to democratize glycoscience.
The National Science Foundation is investing in advanced biofoundries to accelerate biomanufacturing innovations. These facilities will integrate synthetic biology, AI, and automation to tackle global challenges, democratizing access to cutting-edge research tools and transforming fields from healthcare to sustainability.
Scientists have developed a solid-phase-supported chemoenzymatic method to synthesize chondroitin sulfate proteoglycan (CSPG) glycopeptides. This innovative approach offers precise control over GAG chain structures, enabling deeper insights into their biological roles and potential applications in therapeutic development.
That development of cutting-edge tools and technologies in the glycosciences can be achieved through leveraging recent advances in informatics, enzymology, protein engineering, and analytics, and these achievements will lead to transformational and conceptual advances in the glycosciences across the tree of life.
Ph.D. Principal Investigator BioF:GREAT
Ph.D., Co-PI, Director of Knowledge Sharing, BioF:GREAT
Ph.D. Co-PI, Director of User Facility, BioF:GREAT
Ph.D. Co-PI, Director of Research, BioF:GREAT
with the BioFoundry, we have a mandate to expand that to an all-species space, from bacteria to plants to microbes—basically all of biology—to understand the enzymes involved in glycan production, how they work, and what are the types of structures they make.”
Director of Research
Our BioFoundry mandate extends to all-species research, encompassing bacteria, plants, and microbes—essentially all biological systems—to explore glycan-producing enzymes, their mechanisms, and the structures they form.
Principal Investigator